BSP:MRCK34 (USA)
Business Description
Merck & Co Inc
NAICS : 325412
SIC : 2834
2000 Galloping Hill Road, Kenilworth, NJ, USA, 07033
Compare
Compare
Traded in other countries / regions
MRK.Argentina
•
MRK.Austria
•
MRCK34.Brazil
•
MRK.Chile
•
MRK.France
•
6MK.Germany
•
MRK.Mexico
•
MRK.Peru
•
MRK.Romania
•
MRK.Switzerland
•
0QAH.UK
•
MRK.USA
Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 0.73 | |||||
Debt-to-EBITDA | 1.37 | |||||
Interest Coverage | 21.8 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 4.12 | |||||
Beneish M-Score | -2.32 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.7 | |||||
3-Year EBITDA Growth Rate | 10.5 | |||||
3-Year EPS without NRI Growth Rate | 28 | |||||
3-Year FCF Growth Rate | 7.1 | |||||
3-Year Book Growth Rate | 13.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Industry Rank | 10.5 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | 7.91 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.99 | |||||
9-Day RSI | 40.75 | |||||
14-Day RSI | 42.36 | |||||
6-1 Month Momentum % | 26.23 | |||||
12-1 Month Momentum % | 29.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.39 | |||||
Quick Ratio | 1.15 | |||||
Cash Ratio | 0.44 | |||||
Days Inventory | 143.02 | |||||
Days Sales Outstanding | 57.61 | |||||
Days Payable | 82.27 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.15 | |||||
Dividend Payout Ratio | 0.42 | |||||
3-Year Dividend Growth Rate | 9.9 | |||||
Forward Dividend Yield % | 3.18 | |||||
5-Year Yield-on-Cost % | 4.65 | |||||
3-Year Average Share Buyback Ratio | 0.8 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.4 | |||||
Operating Margin % | 33.87 | |||||
Net Margin % | 29 | |||||
ROE % | 43.31 | |||||
ROA % | 16.46 | |||||
ROIC % | 23.97 | |||||
ROC (Joel Greenblatt) % | 96.2 | |||||
ROCE % | 24.97 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 13.62 | |||||
Forward PE Ratio | 12.2 | |||||
PE Ratio without NRI | 13.56 | |||||
Shiller PE Ratio | 27.22 | |||||
Price-to-Owner-Earnings | 16.1 | |||||
PEG Ratio | 1.78 | |||||
PS Ratio | 3.95 | |||||
PB Ratio | 5.21 | |||||
Price-to-Free-Cash-Flow | 15.68 | |||||
Price-to-Operating-Cash-Flow | 11.94 | |||||
EV-to-EBIT | 12.72 | |||||
EV-to-Forward-EBIT | 11.07 | |||||
EV-to-EBITDA | 10.7 | |||||
EV-to-Forward-EBITDA | 10.52 | |||||
EV-to-Revenue | 4.32 | |||||
EV-to-Forward-Revenue | 4.22 | |||||
EV-to-FCF | 17.14 | |||||
Price-to-Projected-FCF | 1.89 | |||||
Price-to-Median-PS-Value | 0.96 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.52 | |||||
Earnings Yield (Greenblatt) % | 7.86 | |||||
Forward Rate of Return (Yacktman) % | 12.7 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil R$) | 298,690.691 | ||
EPS (TTM) (R$) | 4.269 | ||
Beta | -0.33 | ||
Volatility % | 32.7 | ||
14-Day RSI | 42.36 | ||
14-Day ATR (R$) | 1.612918 | ||
20-Day SMA (R$) | 59.1575 | ||
12-1 Month Momentum % | 29.01 | ||
52-Week Range (R$) | 45.5 - 65 | ||
Shares Outstanding (Mil) | 20,266.24 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Merck & Co Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |